Invitrogen, part of Life Technologies Corporation, announced the launch of Prodigy system .The Prodigy microarray system is designed to simplify immunogenetic testing, including human leukocyte antigen (HLA) research. It is an advanced DNA and protein analysis tool that simplifies and accelerates histocompatibility research, drug and vaccine development, and disease association studies.
The Prodigy system is a sequence-specific oligonucleotide probe system that streamlines sample workflow for hybridizing, detecting and analyzing HLA markers in large-volume variation analysis and genotyping research studies. The Prodigy system decreases variability, errors and the need for repeat testing through its simplified workflow reducing hands-on interaction with the system.
The Prodigy system has 5-times the density capacity of current bead-based assays. The push-button, walk-away automation enables researchers to spend valuable time reviewing data or preparing more samples. Prodigy is inherently scalable to include multiplexing capability for more than 500 analytes, while providing high resolution and unmatched efficiency and reliability.
The Prodigy system’s integrated software simplifies data analysis and interpretation. It is also capable of industry-leading throughput that equates to approximately 290 genotypes in 9 hours. With more than 500 analytes capacity, the Prodigy system is uniquely scalable to accommodate new alleles to be identified in the future, enabling it to be easily incorporated into existing infrastructure.
“The development of the Prodigy microarray system is the latest development in Invitrogen’s strategy to make its best-in-class genomic and proteomic technologies available within the HLA research field. This powerful system provides an end-to-end solution that will help researchers advance their immunogenetic studies.” said Jim Janicki, VP & General Manager of Life Technologies’ Transplantation Diagnostics Business